COVID-19 patients with hypertension are at potential risk of worsened organ injury
Abstract In less than 6 months, COVID-19 spread rapidly around the world and became a global health concern. Hypertension is the most common chronic disease in COVID-19 patients, but its impact on these patients has not been well described. In this retrospective study, 82 patients diagnosed with COV...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-83295-w |
| _version_ | 1818691993767772160 |
|---|---|
| author | Fei Xia Mingwei Zhang Bo Cui Wei An Min Chen Ping Yang Tao Qin Xiaoyang Zhou Yaling Liao Xin Xu Shiguo Liu Kuangyu Li Qin Zhou Keke Wang Guangxu Hu Ming Du Songrui Chen Yafang Zhang Wei Wei Ming Xiang Jianjun Zhang |
| author_facet | Fei Xia Mingwei Zhang Bo Cui Wei An Min Chen Ping Yang Tao Qin Xiaoyang Zhou Yaling Liao Xin Xu Shiguo Liu Kuangyu Li Qin Zhou Keke Wang Guangxu Hu Ming Du Songrui Chen Yafang Zhang Wei Wei Ming Xiang Jianjun Zhang |
| author_sort | Fei Xia |
| collection | DOAJ |
| description | Abstract In less than 6 months, COVID-19 spread rapidly around the world and became a global health concern. Hypertension is the most common chronic disease in COVID-19 patients, but its impact on these patients has not been well described. In this retrospective study, 82 patients diagnosed with COVID-19 were enrolled, and epidemiological, demographic, clinical, laboratory, radiological and therapy-related data were analyzed and compared between COVID-19 patients with (29 cases) or without (53 cases) hypertension. The median age of the included patients was 60.5 years, and the cohort included 49 women (59.8%) and 33 (40.2%) men. Hypertension (31 [28.2%]) was the most common chronic illness, followed by diabetes (16 [19.5%]) and cardiovascular disease (15 [18.3%]). The most common symptoms were fatigue (55 [67.1%]), dry cough (46 [56.1%]) and fever ≥ 37.3 °C (46 [56.1%]). The median time from illness onset to positive RT-PCR test was 13.0 days (range 3–25 days). There were 6 deaths (20.7%) in the hypertension group and 5 deaths (9.4%) in the nonhypertension group, and more hypertensive patients with COVID-19 (8 [27.6%]) than nonhypertensive patients (2 [3.8%]) (P = 0.002) had at least one comorbid disease. Compared with nonhypertensive patients, hypertensive patients exhibited higher neutrophil counts, serum amyloid A, C-reactive protein, and NT-proBNP and lower lymphocyte counts and eGFR. Dynamic observations indicated more severe disease and poorer outcomes after hospital admission in the hypertension group. COVID-19 patients with hypertension have increased risks of severe inflammatory reactions, serious internal organ injury, and disease progression and deterioration. |
| first_indexed | 2024-12-17T12:50:43Z |
| format | Article |
| id | doaj.art-df503a4f88e946b59828c938ecbdb154 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-17T12:50:43Z |
| publishDate | 2021-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-df503a4f88e946b59828c938ecbdb1542022-12-21T21:47:37ZengNature PortfolioScientific Reports2045-23222021-02-0111111010.1038/s41598-021-83295-wCOVID-19 patients with hypertension are at potential risk of worsened organ injuryFei Xia0Mingwei Zhang1Bo Cui2Wei An3Min Chen4Ping Yang5Tao Qin6Xiaoyang Zhou7Yaling Liao8Xin Xu9Shiguo Liu10Kuangyu Li11Qin Zhou12Keke Wang13Guangxu Hu14Ming Du15Songrui Chen16Yafang Zhang17Wei Wei18Ming Xiang19Jianjun Zhang20Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan UniversityDepartment of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan UniversityDepartment of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Pharmacy, The First Affiliated Hospital of China Medical UniversityDepartment of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Clinical Pharmacy, Hubei No. 3 People’s Hospital of Jianghan University (the Third People’s Hospital of Hubei Province)Abstract In less than 6 months, COVID-19 spread rapidly around the world and became a global health concern. Hypertension is the most common chronic disease in COVID-19 patients, but its impact on these patients has not been well described. In this retrospective study, 82 patients diagnosed with COVID-19 were enrolled, and epidemiological, demographic, clinical, laboratory, radiological and therapy-related data were analyzed and compared between COVID-19 patients with (29 cases) or without (53 cases) hypertension. The median age of the included patients was 60.5 years, and the cohort included 49 women (59.8%) and 33 (40.2%) men. Hypertension (31 [28.2%]) was the most common chronic illness, followed by diabetes (16 [19.5%]) and cardiovascular disease (15 [18.3%]). The most common symptoms were fatigue (55 [67.1%]), dry cough (46 [56.1%]) and fever ≥ 37.3 °C (46 [56.1%]). The median time from illness onset to positive RT-PCR test was 13.0 days (range 3–25 days). There were 6 deaths (20.7%) in the hypertension group and 5 deaths (9.4%) in the nonhypertension group, and more hypertensive patients with COVID-19 (8 [27.6%]) than nonhypertensive patients (2 [3.8%]) (P = 0.002) had at least one comorbid disease. Compared with nonhypertensive patients, hypertensive patients exhibited higher neutrophil counts, serum amyloid A, C-reactive protein, and NT-proBNP and lower lymphocyte counts and eGFR. Dynamic observations indicated more severe disease and poorer outcomes after hospital admission in the hypertension group. COVID-19 patients with hypertension have increased risks of severe inflammatory reactions, serious internal organ injury, and disease progression and deterioration.https://doi.org/10.1038/s41598-021-83295-w |
| spellingShingle | Fei Xia Mingwei Zhang Bo Cui Wei An Min Chen Ping Yang Tao Qin Xiaoyang Zhou Yaling Liao Xin Xu Shiguo Liu Kuangyu Li Qin Zhou Keke Wang Guangxu Hu Ming Du Songrui Chen Yafang Zhang Wei Wei Ming Xiang Jianjun Zhang COVID-19 patients with hypertension are at potential risk of worsened organ injury Scientific Reports |
| title | COVID-19 patients with hypertension are at potential risk of worsened organ injury |
| title_full | COVID-19 patients with hypertension are at potential risk of worsened organ injury |
| title_fullStr | COVID-19 patients with hypertension are at potential risk of worsened organ injury |
| title_full_unstemmed | COVID-19 patients with hypertension are at potential risk of worsened organ injury |
| title_short | COVID-19 patients with hypertension are at potential risk of worsened organ injury |
| title_sort | covid 19 patients with hypertension are at potential risk of worsened organ injury |
| url | https://doi.org/10.1038/s41598-021-83295-w |
| work_keys_str_mv | AT feixia covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT mingweizhang covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT bocui covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT weian covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT minchen covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT pingyang covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT taoqin covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT xiaoyangzhou covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT yalingliao covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT xinxu covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT shiguoliu covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT kuangyuli covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT qinzhou covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT kekewang covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT guangxuhu covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT mingdu covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT songruichen covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT yafangzhang covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT weiwei covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT mingxiang covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury AT jianjunzhang covid19patientswithhypertensionareatpotentialriskofworsenedorganinjury |